Ocugen, Inc. (OCGN)Healthcare | Biotechnology | Malvern, United States | NasdaqCM
1.32 USD
-0.05
(-3.650%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 1.35 +0.03 (2.273%) ⇧ (Aug. 28, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:43 a.m. EDT
The investment case for Ocugen is currently defined by a stark disconnect between optimistic analyst targets and deteriorating financial reality. While analysts project a mean price of $12.17, the company's fundamentals tell a different story: negative earnings, negative free cash flow, and a book value that is effectively zero or negative. The stock has suffered a catastrophic 99.4% decline over the last nine years, with the most recent annual performance showing another drop. This multi-year structural decline suggests the market has already priced out the worst-case scenarios regarding the business's ability to generate sustainable value. Short-term momentum remains fragile. The stock is trading below its 200-day moving average, and the statistical forecasting model offers no directional edge, reflecting the high noise-to-signal ratio typical of distressed biotech stocks. Options activity confirms this pessimism, with traders aggressively buying deep out-of-the-money puts to hedge against further drops rather than betting on a rally. There is no dividend income to offset these risks. The company is burning cash, and the recent capital raises, while providing temporary liquidity, highlight the lack of organic funding. Until there is concrete evidence of sustained profitability or a definitive path to commercialization that translates into revenue growth, the long-term outlook remains severely compromised. The current price reflects a high-risk environment where the potential for total capital loss is significant. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.071152 |
| AutoETS | 0.071152 |
| MSTL | 0.073443 |
| AutoTheta | 0.192476 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 0.49 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.193 |
| Excess Kurtosis | -0.61 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.014 |
| Market Cap | 447,625,760 |
| Forward P/E | -4.95 |
| Beta | 2.20 |
| Website | https://www.ocugen.com |
As of Aug. 22, 2026, 4:43 a.m. EDT: Speculators are heavily positioned for downside protection, with put open interest significantly outweighing call open interest across all expirations. Deep out-of-the-money puts show massive volume spikes relative to their open interest, indicating aggressive hedging or bearish bets on further declines. Conversely, call positioning is concentrated in the money and at-the-money strikes, suggesting limited speculative upside conviction despite the high implied volatility.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.2815534 |
| Address1 | 11 Great Valley Parkway |
| All Time High | 778.2 |
| All Time Low | 0.17 |
| Ask | 1.53 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 3,376,270 |
| Average Daily Volume3 Month | 6,163,600 |
| Average Volume | 6,163,600 |
| Average Volume10Days | 3,376,270 |
| Beta | 2.203 |
| Bid | 1.33 |
| Bid Size | 4 |
| Book Value | -0.049 |
| City | Malvern |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.32 |
| Current Ratio | 0.802 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 1.37 |
| Day Low | 1.32 |
| Display Name | Ocugen |
| Dividend Date | 1,569,801,600 |
| Earnings Call Timestamp End | 1,786,019,400 |
| Earnings Call Timestamp Start | 1,786,019,400 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -67,173,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.484 |
| Enterprise To Revenue | 95.08 |
| Enterprise Value | 435,560,736 |
| Eps Current Year | -0.27 |
| Eps Forward | -0.26667 |
| Eps Trailing Twelve Months | -0.25 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.3669 |
| Fifty Day Average Change | -0.046899915 |
| Fifty Day Average Change Percent | -0.034311153 |
| Fifty Two Week Change Percent | 28.155338 |
| Fifty Two Week High | 2.725 |
| Fifty Two Week High Change | -1.4049999 |
| Fifty Two Week High Change Percent | -0.5155963 |
| Fifty Two Week Low | 1.0 |
| Fifty Two Week Low Change | 0.32000005 |
| Fifty Two Week Low Change Percent | 0.32000005 |
| Fifty Two Week Range | 1.0 - 2.725 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,417,617,000,000 |
| Float Shares | 333,389,609 |
| Forward Eps | -0.26667 |
| Forward P E | -4.9499383 |
| Free Cashflow | -1,974,375 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 116 |
| Fullday Change | -0.05 |
| Fullday Change Percent | -3.64963 |
| Fullday Price | 1.35 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -39,182,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01681 |
| Held Percent Institutions | 0.43295 |
| Implied Shares Outstanding | 339,110,401 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,569,801,600 |
| Last Split Factor | 1:60 |
| Long Business Summary | Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. |
| Long Name | Ocugen, Inc. |
| Market | us_market |
| Market Cap | 447,625,760 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_303874231 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -81,811,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 464,581,249 |
| Number Of Analyst Opinions | 6 |
| Open | 1.36 |
| Operating Cashflow | -60,869,000 |
| Operating Margins | -11.051081 |
| Payout Ratio | 0.0 |
| Phone | 484 328 4701 |
| Post Market Change | 0.029999971 |
| Post Market Change Percent | 2.272725 |
| Post Market Price | 1.35 |
| Post Market Time | 1,787,961,599 |
| Previous Close | 1.37 |
| Price Eps Current Year | -4.888889 |
| Price Hint | 4 |
| Price To Book | -26.938778 |
| Price To Sales Trailing12 Months | 97.71355 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.752 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.05 |
| Regular Market Change Percent | -3.64963 |
| Regular Market Day High | 1.37 |
| Regular Market Day Low | 1.32 |
| Regular Market Day Range | 1.32 - 1.37 |
| Regular Market Open | 1.36 |
| Regular Market Previous Close | 1.37 |
| Regular Market Price | 1.32 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 3,045,378 |
| Return On Assets | -0.48441002 |
| Revenue Growth | 0.084 |
| Revenue Per Share | 0.014 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 339,110,401 |
| Shares Percent Shares Out | 0.3001 |
| Shares Short | 101,770,376 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 100,590,405 |
| Short Name | Ocugen, Inc. |
| Short Percent Of Float | 0.3017 |
| Short Ratio | 22.65 |
| Source Interval | 15 |
| State | PA |
| Symbol | OCGN |
| Target High Price | 22.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 12.16667 |
| Target Median Price | 10.5 |
| Total Cash | 100,051,000 |
| Total Cash Per Share | 0.295 |
| Total Debt | 87,986,000 |
| Total Revenue | 4,581,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.25 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.5082 |
| Two Hundred Day Average Change | -0.1882 |
| Two Hundred Day Average Change Percent | -0.12478451 |
| Type Disp | Equity |
| Volume | 3,045,378 |
| Website | https://www.ocugen.com |
| Zip | 19,355 |